Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center
Advertisement
Articles by Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center
Advertisement
Latest Updated Articles
Recent Updates to NCCN Guidelines on MF TreatmentPublished: July 6th 2021 | Updated:
Bone Marrow Transplant for Patients With MFPublished: July 20th 2021 | Updated:
Myeloproliferative Neoplasms: Essential ThrombocythemiaPublished: June 29th 2022 | Updated:
- Managing Patients with Essential Thrombocythemia
Published: June 29th 2022 | Updated:
Monitoring Disease Response or Progression in MFPublished: July 6th 2021 | Updated:
Fedratinib for Patients With Primary MyelofibrosisPublished: July 13th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5